S1PR2 and central nervous system cancer: Furthermore, S1P2 inhibited NADPH oxidase-3 activity in a recombinant system, and the S1P2 agonist, CYM-5478, reduced cisplatin-induced ROS formation in C6 glioma cells (Herr et al., 2016).